Gut : liver : brain axis: the microbial challenge in the hepatic encephalopathy
Hepatic encephalopathy (HE) is a debilitating neuropsychiatric condition often associated with acute liver failure or cirrhosis. Advanced liver diseases are characterized by a leaky gut and systemic inflammation. There is strong evidence that the pathogenesis of HE is linked to a dysbiotic gut micro...
Gespeichert in:
Veröffentlicht in: | Food & function 2018-03, Vol.9 (3), p.1373-1388 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 1388 |
---|---|
container_issue | 3 |
container_start_page | 1373 |
container_title | Food & function |
container_volume | 9 |
creator | Mancini, Andrea Campagna, Francesca Amodio, Piero Tuohy, Kieran M |
description | Hepatic encephalopathy (HE) is a debilitating neuropsychiatric condition often associated with acute liver failure or cirrhosis. Advanced liver diseases are characterized by a leaky gut and systemic inflammation. There is strong evidence that the pathogenesis of HE is linked to a dysbiotic gut microbiota and to harmful microbial by-products, such as ammonia, indoles, oxindoles and endotoxins. Increased concentrations of these toxic metabolites together with the inability of the diseased liver to clear such products is thought to play an important patho-ethiological role. Current first line clinical treatments target microbiota dysbiosis by decreasing the counts of pathogenic bacteria, blood endotoxemia and ammonia levels. This review will focus on the role of the gut microbiota and its metabolism in HE and advanced cirrhosis. It will critically assess data from different clinical trials measuring the efficacy of the prebiotic lactulose, the probiotic VSL#3 and the antibiotic rifaximin in treating HE and advanced cirrhosis, through gut microbiota modulation. Additionally data from Randomised Controlled Trials using pre-, pro- and synbiotic will be also considered by reporting meta-analysis studies. The large amount of existing data showed that HE is a clear example of how an altered gut microbiota homeostasis can influence and impact on physiological functions outside the intestine, with implication for host health at the systems level. Nevertheless, a strong effort should be made to increase the information on gut microbiota ecology and its metabolic function in liver diseases and HE.
Gut microbiota modulation to restore proper gut : brain axis communications and reduce cirrhosis associated symptoms and HE progression. |
doi_str_mv | 10.1039/c7fo01528c |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmed_primary_29485654</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2015821465</sourcerecordid><originalsourceid>FETCH-LOGICAL-c444t-eca438a2f0a7cde37a635091e23582890749981e78c02cc3c692ce788eeb80313</originalsourceid><addsrcrecordid>eNpFkU1Lw0AQhhdRbKm9eFcC3oTofiXZ7U2CrUKhF0VvYbOdmJQ0ibuJ2JtX_6a_xK1p68KwM7wPM7vvIHRO8A3BTN7qKKsxCajQR2hIMad-GODX433OZThAY2tX2B0mpZDiFA2o5CIIAz5EL7Ou_fn6nrgoiw8wuzw1qqg89VnYidfm4K0Lbeq0UKWnc1WWUL2B54CtlEOj2kJ7UGlonFi7Mt-coZNMlRbGu3uEnqf3T_GDP1_MHuO7ua85560PWnEmFM2wivQSWKRCFmBJgLJAUCFxxN2bCURCY6o106Gk2lUCIBWYETZCV33fxtTvHdg2WdWdqdzIhDpbBCU8DBx13VPuF9YayJLGFGtlNgnBydbGJI6miz8bYwdf7lp26RqWB3RvmgMuesBYfVD_98B-AV7QeYM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2015821465</pqid></control><display><type>article</type><title>Gut : liver : brain axis: the microbial challenge in the hepatic encephalopathy</title><source>Royal Society Of Chemistry Journals 2008-</source><creator>Mancini, Andrea ; Campagna, Francesca ; Amodio, Piero ; Tuohy, Kieran M</creator><creatorcontrib>Mancini, Andrea ; Campagna, Francesca ; Amodio, Piero ; Tuohy, Kieran M</creatorcontrib><description>Hepatic encephalopathy (HE) is a debilitating neuropsychiatric condition often associated with acute liver failure or cirrhosis. Advanced liver diseases are characterized by a leaky gut and systemic inflammation. There is strong evidence that the pathogenesis of HE is linked to a dysbiotic gut microbiota and to harmful microbial by-products, such as ammonia, indoles, oxindoles and endotoxins. Increased concentrations of these toxic metabolites together with the inability of the diseased liver to clear such products is thought to play an important patho-ethiological role. Current first line clinical treatments target microbiota dysbiosis by decreasing the counts of pathogenic bacteria, blood endotoxemia and ammonia levels. This review will focus on the role of the gut microbiota and its metabolism in HE and advanced cirrhosis. It will critically assess data from different clinical trials measuring the efficacy of the prebiotic lactulose, the probiotic VSL#3 and the antibiotic rifaximin in treating HE and advanced cirrhosis, through gut microbiota modulation. Additionally data from Randomised Controlled Trials using pre-, pro- and synbiotic will be also considered by reporting meta-analysis studies. The large amount of existing data showed that HE is a clear example of how an altered gut microbiota homeostasis can influence and impact on physiological functions outside the intestine, with implication for host health at the systems level. Nevertheless, a strong effort should be made to increase the information on gut microbiota ecology and its metabolic function in liver diseases and HE.
Gut microbiota modulation to restore proper gut : brain axis communications and reduce cirrhosis associated symptoms and HE progression.</description><identifier>ISSN: 2042-6496</identifier><identifier>EISSN: 2042-650X</identifier><identifier>DOI: 10.1039/c7fo01528c</identifier><identifier>PMID: 29485654</identifier><language>eng</language><publisher>England: Royal Society of Chemistry</publisher><subject>Ammonia ; Antibiotics ; Brain ; Cirrhosis ; Clinical trials ; Digestive system ; Dysbacteriosis ; Endotoxemia ; Endotoxins ; Gastrointestinal tract ; Hepatic encephalopathy ; Homeostasis ; Indoles ; Intestinal microflora ; Intestine ; Lactulose ; Liver ; Liver cirrhosis ; Liver diseases ; Medical research ; Metabolism ; Metabolites ; Microbiota ; Microorganisms ; Pathogenesis ; Probiotics</subject><ispartof>Food & function, 2018-03, Vol.9 (3), p.1373-1388</ispartof><rights>Copyright Royal Society of Chemistry 2018</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c444t-eca438a2f0a7cde37a635091e23582890749981e78c02cc3c692ce788eeb80313</citedby><cites>FETCH-LOGICAL-c444t-eca438a2f0a7cde37a635091e23582890749981e78c02cc3c692ce788eeb80313</cites><orcidid>0000-0002-2395-7599 ; 0000-0001-6882-7192 ; 0000-0002-3596-6345 ; 0000-0002-7154-7121</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29485654$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mancini, Andrea</creatorcontrib><creatorcontrib>Campagna, Francesca</creatorcontrib><creatorcontrib>Amodio, Piero</creatorcontrib><creatorcontrib>Tuohy, Kieran M</creatorcontrib><title>Gut : liver : brain axis: the microbial challenge in the hepatic encephalopathy</title><title>Food & function</title><addtitle>Food Funct</addtitle><description>Hepatic encephalopathy (HE) is a debilitating neuropsychiatric condition often associated with acute liver failure or cirrhosis. Advanced liver diseases are characterized by a leaky gut and systemic inflammation. There is strong evidence that the pathogenesis of HE is linked to a dysbiotic gut microbiota and to harmful microbial by-products, such as ammonia, indoles, oxindoles and endotoxins. Increased concentrations of these toxic metabolites together with the inability of the diseased liver to clear such products is thought to play an important patho-ethiological role. Current first line clinical treatments target microbiota dysbiosis by decreasing the counts of pathogenic bacteria, blood endotoxemia and ammonia levels. This review will focus on the role of the gut microbiota and its metabolism in HE and advanced cirrhosis. It will critically assess data from different clinical trials measuring the efficacy of the prebiotic lactulose, the probiotic VSL#3 and the antibiotic rifaximin in treating HE and advanced cirrhosis, through gut microbiota modulation. Additionally data from Randomised Controlled Trials using pre-, pro- and synbiotic will be also considered by reporting meta-analysis studies. The large amount of existing data showed that HE is a clear example of how an altered gut microbiota homeostasis can influence and impact on physiological functions outside the intestine, with implication for host health at the systems level. Nevertheless, a strong effort should be made to increase the information on gut microbiota ecology and its metabolic function in liver diseases and HE.
Gut microbiota modulation to restore proper gut : brain axis communications and reduce cirrhosis associated symptoms and HE progression.</description><subject>Ammonia</subject><subject>Antibiotics</subject><subject>Brain</subject><subject>Cirrhosis</subject><subject>Clinical trials</subject><subject>Digestive system</subject><subject>Dysbacteriosis</subject><subject>Endotoxemia</subject><subject>Endotoxins</subject><subject>Gastrointestinal tract</subject><subject>Hepatic encephalopathy</subject><subject>Homeostasis</subject><subject>Indoles</subject><subject>Intestinal microflora</subject><subject>Intestine</subject><subject>Lactulose</subject><subject>Liver</subject><subject>Liver cirrhosis</subject><subject>Liver diseases</subject><subject>Medical research</subject><subject>Metabolism</subject><subject>Metabolites</subject><subject>Microbiota</subject><subject>Microorganisms</subject><subject>Pathogenesis</subject><subject>Probiotics</subject><issn>2042-6496</issn><issn>2042-650X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNpFkU1Lw0AQhhdRbKm9eFcC3oTofiXZ7U2CrUKhF0VvYbOdmJQ0ibuJ2JtX_6a_xK1p68KwM7wPM7vvIHRO8A3BTN7qKKsxCajQR2hIMad-GODX433OZThAY2tX2B0mpZDiFA2o5CIIAz5EL7Ou_fn6nrgoiw8wuzw1qqg89VnYidfm4K0Lbeq0UKWnc1WWUL2B54CtlEOj2kJ7UGlonFi7Mt-coZNMlRbGu3uEnqf3T_GDP1_MHuO7ua85560PWnEmFM2wivQSWKRCFmBJgLJAUCFxxN2bCURCY6o106Gk2lUCIBWYETZCV33fxtTvHdg2WdWdqdzIhDpbBCU8DBx13VPuF9YayJLGFGtlNgnBydbGJI6miz8bYwdf7lp26RqWB3RvmgMuesBYfVD_98B-AV7QeYM</recordid><startdate>20180301</startdate><enddate>20180301</enddate><creator>Mancini, Andrea</creator><creator>Campagna, Francesca</creator><creator>Amodio, Piero</creator><creator>Tuohy, Kieran M</creator><general>Royal Society of Chemistry</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7T7</scope><scope>7TO</scope><scope>7U7</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>P64</scope><orcidid>https://orcid.org/0000-0002-2395-7599</orcidid><orcidid>https://orcid.org/0000-0001-6882-7192</orcidid><orcidid>https://orcid.org/0000-0002-3596-6345</orcidid><orcidid>https://orcid.org/0000-0002-7154-7121</orcidid></search><sort><creationdate>20180301</creationdate><title>Gut : liver : brain axis: the microbial challenge in the hepatic encephalopathy</title><author>Mancini, Andrea ; Campagna, Francesca ; Amodio, Piero ; Tuohy, Kieran M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c444t-eca438a2f0a7cde37a635091e23582890749981e78c02cc3c692ce788eeb80313</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Ammonia</topic><topic>Antibiotics</topic><topic>Brain</topic><topic>Cirrhosis</topic><topic>Clinical trials</topic><topic>Digestive system</topic><topic>Dysbacteriosis</topic><topic>Endotoxemia</topic><topic>Endotoxins</topic><topic>Gastrointestinal tract</topic><topic>Hepatic encephalopathy</topic><topic>Homeostasis</topic><topic>Indoles</topic><topic>Intestinal microflora</topic><topic>Intestine</topic><topic>Lactulose</topic><topic>Liver</topic><topic>Liver cirrhosis</topic><topic>Liver diseases</topic><topic>Medical research</topic><topic>Metabolism</topic><topic>Metabolites</topic><topic>Microbiota</topic><topic>Microorganisms</topic><topic>Pathogenesis</topic><topic>Probiotics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mancini, Andrea</creatorcontrib><creatorcontrib>Campagna, Francesca</creatorcontrib><creatorcontrib>Amodio, Piero</creatorcontrib><creatorcontrib>Tuohy, Kieran M</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Biotechnology and BioEngineering Abstracts</collection><jtitle>Food & function</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mancini, Andrea</au><au>Campagna, Francesca</au><au>Amodio, Piero</au><au>Tuohy, Kieran M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Gut : liver : brain axis: the microbial challenge in the hepatic encephalopathy</atitle><jtitle>Food & function</jtitle><addtitle>Food Funct</addtitle><date>2018-03-01</date><risdate>2018</risdate><volume>9</volume><issue>3</issue><spage>1373</spage><epage>1388</epage><pages>1373-1388</pages><issn>2042-6496</issn><eissn>2042-650X</eissn><abstract>Hepatic encephalopathy (HE) is a debilitating neuropsychiatric condition often associated with acute liver failure or cirrhosis. Advanced liver diseases are characterized by a leaky gut and systemic inflammation. There is strong evidence that the pathogenesis of HE is linked to a dysbiotic gut microbiota and to harmful microbial by-products, such as ammonia, indoles, oxindoles and endotoxins. Increased concentrations of these toxic metabolites together with the inability of the diseased liver to clear such products is thought to play an important patho-ethiological role. Current first line clinical treatments target microbiota dysbiosis by decreasing the counts of pathogenic bacteria, blood endotoxemia and ammonia levels. This review will focus on the role of the gut microbiota and its metabolism in HE and advanced cirrhosis. It will critically assess data from different clinical trials measuring the efficacy of the prebiotic lactulose, the probiotic VSL#3 and the antibiotic rifaximin in treating HE and advanced cirrhosis, through gut microbiota modulation. Additionally data from Randomised Controlled Trials using pre-, pro- and synbiotic will be also considered by reporting meta-analysis studies. The large amount of existing data showed that HE is a clear example of how an altered gut microbiota homeostasis can influence and impact on physiological functions outside the intestine, with implication for host health at the systems level. Nevertheless, a strong effort should be made to increase the information on gut microbiota ecology and its metabolic function in liver diseases and HE.
Gut microbiota modulation to restore proper gut : brain axis communications and reduce cirrhosis associated symptoms and HE progression.</abstract><cop>England</cop><pub>Royal Society of Chemistry</pub><pmid>29485654</pmid><doi>10.1039/c7fo01528c</doi><tpages>16</tpages><orcidid>https://orcid.org/0000-0002-2395-7599</orcidid><orcidid>https://orcid.org/0000-0001-6882-7192</orcidid><orcidid>https://orcid.org/0000-0002-3596-6345</orcidid><orcidid>https://orcid.org/0000-0002-7154-7121</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2042-6496 |
ispartof | Food & function, 2018-03, Vol.9 (3), p.1373-1388 |
issn | 2042-6496 2042-650X |
language | eng |
recordid | cdi_pubmed_primary_29485654 |
source | Royal Society Of Chemistry Journals 2008- |
subjects | Ammonia Antibiotics Brain Cirrhosis Clinical trials Digestive system Dysbacteriosis Endotoxemia Endotoxins Gastrointestinal tract Hepatic encephalopathy Homeostasis Indoles Intestinal microflora Intestine Lactulose Liver Liver cirrhosis Liver diseases Medical research Metabolism Metabolites Microbiota Microorganisms Pathogenesis Probiotics |
title | Gut : liver : brain axis: the microbial challenge in the hepatic encephalopathy |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-22T20%3A00%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Gut%E2%80%89:%E2%80%89liver%E2%80%89:%E2%80%89brain%20axis:%20the%20microbial%20challenge%20in%20the%20hepatic%20encephalopathy&rft.jtitle=Food%20&%20function&rft.au=Mancini,%20Andrea&rft.date=2018-03-01&rft.volume=9&rft.issue=3&rft.spage=1373&rft.epage=1388&rft.pages=1373-1388&rft.issn=2042-6496&rft.eissn=2042-650X&rft_id=info:doi/10.1039/c7fo01528c&rft_dat=%3Cproquest_pubme%3E2015821465%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2015821465&rft_id=info:pmid/29485654&rfr_iscdi=true |